

Coverage — original cohort and new sources kept separate

142 included observations | 12 suppliers | Captures: 14 September 2026

All 295 original records have a recorded outcome, but not all were successfully retrieved or usable. 7 additional candidates were considered separately. Exclusion is not an accusation or a live-site deletion.

Catalog label	Original included / total	Original excluded	New included / total	New excluded
aod-9604	8 / 10	2	0 / 0	0
bpc-157	8 / 14	6	0 / 0	0
cagrilintide	2 / 3	1	0 / 0	0
cjc-1295	8 / 18	10	0 / 0	0
dsip	5 / 9	4	0 / 0	0
epithalon	7 / 12	5	0 / 0	0
fox04-dri	2 / 2	0	0 / 0	0
ghk-cu	6 / 15	9	0 / 0	0
ghrp-2	5 / 13	8	0 / 0	0
ghrp-6	6 / 14	8	0 / 0	0
hexarelin	2 / 5	3	0 / 0	0
hgh-fragment-176-191	2 / 3	1	0 / 0	0
humanin	1 / 1	0	0 / 0	0
igf-1-lr3	5 / 9	4	0 / 0	0
ipamorelin	6 / 15	9	0 / 0	0
kisspeptin	3 / 9	6	0 / 0	0
kpv	7 / 13	6	0 / 0	0
ll-37	4 / 4	0	0 / 0	0
melanotan-ii	1 / 4	3	0 / 0	0
mots-c	5 / 11	6	0 / 0	0
nad-plus	3 / 5	2	0 / 0	0
oxytocin	5 / 10	5	0 / 0	0
peg-mgf	2 / 5	3	0 / 0	0
pt-141	7 / 10	3	0 / 0	0
retatrutide	0 / 12	12	1 / 2	1
selank	4 / 9	5	0 / 0	0
semaglutide	0 / 3	3	1 / 4	3
semax	4 / 8	4	0 / 0	0
sermorelin	5 / 11	6	0 / 0	0
tb-500	5 / 12	7	0 / 0	0
tesamorelin	6 / 11	5	0 / 0	0
thymosin-alpha-1	5 / 10	5	0 / 0	0
tirzepatide	0 / 5	5	1 / 1	0

TOTAL	139 / 295	156	3 / 7	4
-------	-----------	-----	-------	---

Tax classes stay distinct in individual records; no prices are pooled. Catalog labels are not independent chemical identification; NAD+ is retained as a catalog compound, not asserted to be a peptide.

Supplier in-stock wording is a dated claim, not checkout, dispatch or live availability. GB database codes and UK-facing first-party assertions do not verify legal domicile. Coverage is purposive and source-access dependent, not national-market completeness.

Prepared for Peptide Scanner, whose captured disclaimer discloses possible affiliate referral fees. This source-content review did not contact suppliers or press, change live prices, deploy software, or validate assays. Read the methodology and full exclusion ledger alongside these counts.